Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

1 article from the last 30 days matching "semaglutide"

🔴 BreakingDrug approvalRSSApr 3

FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide

The FDA approved a new, stronger version of the weight loss drug Wegovy (semaglutide) at 7.2 mg. This higher dose is intended for adults who need help losing weight and keeping it off long-term. This approval was granted under a special FDA program that prioritizes treatments for rare diseases.

WHY IT MATTERSThis approval under the National Priority Voucher Program suggests semaglutide may address weight management in a rare disease population, though the article does not specify which rare condition qualifies for this higher dose.
💬 Ask your doctorRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases